UCB to Acquire Candid Therapeutics in $2.2 Billion Deal
UCB has announced a definitive agreement to acquire Candid Therapeutics in a deal valued at up to $2.2 billion, marking a significant expansion of its immunology pipeline and…
Read More...
Read More...
